CCIA
GLUE icon

Campbell & Co Investment Adviser’s Monte Rosa Therapeutics GLUE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687K Buy
28,375
+11,360
+67% +$215K 0.04% 680
2026
Q1 		$280K Sell
17,015
-73,737
-81% -$1.41M 0.02% 895
2025
Q4 		$1.42M Buy
90,752
+39,619
+77% +$534K 0.07% 437
2025
Q3 		$379K Buy
+51,133
New +$271K 0.03% 825

Other funds holding GLUE

TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return

Campbell & Co Investment Adviser's GLUE Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Monte Rosa Therapeutics (GLUE) stake by 67% in Q2 2026, buying an estimated $215K and bringing the position to 28,375 shares worth $687K. The position accounts for 0.04% of the portfolio, ranked #680.

Campbell & Co Investment Adviser first reported a position in GLUE in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.42M in Q4 2025. 28 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Campbell & Co Investment Adviser held 28,375 shares of Monte Rosa Therapeutics worth $687K as of Q2 2026.
  • Campbell & Co Investment Adviser bought 11,360 Monte Rosa Therapeutics shares in Q2 2026, an estimated $215K.
  • Monte Rosa Therapeutics made up 0.04% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #680 holding.
  • Campbell & Co Investment Adviser first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Campbell & Co Investment Adviser's Monte Rosa Therapeutics position peaked at $1.42M in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.